Engflag

Panat

Quick links to important sections

Panat

Panat_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Panat

What is Panat? Composition and Classification

Property Description
Active ingredient Atropine Sulfate, Papaveretum
Form Solution for injection, Tablet
Pharmacological class Anticholinergic and Opioid Analgesic combination
General purpose Management of moderate to severe pain and spasms
Origin Derived from natural plant alkaloids

What Type of Medicine is Panat?

Panat is a fixed-dose combination drug classified with the dual functions of an Anticholinergic Agent and an Opioid Analgesic. This specific structure is crucial, as it targets two distinct physiological processes: the transmission of pain signals and involuntary muscle contraction. The component Atropine Sulfate is broadly classified as a tropane alkaloid and an antimuscarinic agent. Atropine is recognized on lists of essential medicines, reflecting its role in healthcare settings. This combination drug is a prescription-only medication, often reserved for scenarios requiring rapid, profound relief.

Composition and Origin: Atropine Sulfate and Papaveretum

The active ingredients in Panat are Atropine Sulfate and Papaveretum, both of which have origins in naturally occurring plant compounds, classifying them as natural plant alkaloids. The second component, Papaveretum, is a standardized mixture of opium alkaloids. Papaveretum consists of the hydrochloride salts of Morphine, Papaverine, and Codeine, providing a blend of analgesic and antispasmodic substances. Panat is typically formulated as a sterile solution for injection for parenteral administration, allowing for rapid therapeutic effect in acute settings.

General Purpose and Benefit of the Combination

The general purpose of Panat is derived directly from its composition, offering comprehensive management of severe discomfort and associated physiological tension. The opioid analgesic components deliver powerful central pain relief, while the anticholinergic function provides essential peripheral action, particularly the relaxation of smooth muscles. Clinically, the combined approach is utilized for rapidly controlling intense visceral pain where spasm is a significant contributing factor. The practical benefit lies in its ability to quickly manage moderate to severe pain that is often accompanied by cramping or spasm, promoting a state of physiological quietness.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. Proposed omission of Papaveretum from BP

What side effects are possible with Panat?

Possible Side Effects and Safety Information

The following safety information is based strictly on documentation from government health regulatory authorities, including how they classify adverse reactions and safety restrictions for this medicine.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by regulatory bodies based on how frequently they were reported in clinical trials or post-marketing surveillance. Common reactions documented in adult trials (occurring in 2% or more of patients) involve:

  • Nervous System and Musculoskeletal: Headache, dizziness, and joint pain (arthralgia).
  • Gastrointestinal System: Diarrhea, nausea, vomiting, abdominal pain, and flatulence.

Serious and Clinically Significant Adverse Reactions

Official regulatory documents describe several serious or clinically significant risks that may be associated with the medicine, including:

  • Hypersensitivity: Severe allergic reactions, including anaphylaxis.
  • Kidney and Skin Conditions: Acute Tubulointerstitial Nephritis and severe cutaneous reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis).
  • Nutritional and Bone Risks (Long-Term Use): Low magnesium levels (hypomagnesemia) and an increased risk of bone fractures (hip, wrist, spine), particularly with high-dose, long-term use (a year or more). Prolonged daily use (over three years) may also lead to Vitamin B12 deficiency.

Safety-Related Restrictions

The medicine is subject to regulatory restrictions regarding its use. It must not be used (is contraindicated) in patients with a known severe allergy to any of its components or to related medicines (substituted benzimidazoles). Official warnings also state that use of this medicine must be considered in patients with certain co-administered medications.

Population-Specific Safety Notes

The safety profile includes specific considerations for different groups, as documented in regulatory texts. The most frequent side effects in pediatric populations differ somewhat from adults, often including upper respiratory infection and fever. For pregnant or nursing individuals, regulatory guidance is provided to help assess the risks versus the benefits.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define Panat overdose by the combined effects of its Anticholinergic (Atropine) and Opioid (Papaveretum) components. Due to the severe risks involved, seek immediate medical attention for any suspected toxic overdosage or observed severe symptoms. Immediate, intensive supportive therapy is required, as mandated by regulatory statements.

Overdose manifestations can include symptoms of central anticholinergic toxicity, such as excitement, hallucinations, delirium, and coma, alongside signs like dilated pupils, hot dry skin, and palpitation. The simultaneous risk from the opioid component is severe respiratory depression, which can lead to respiratory failure and death.

Life-threatening outcomes officially documented include circulatory collapse and convulsions. Management procedures described in labeling include the use of specific antidotes: Naloxone for the opioid component and Physostigmine for the central anticholinergic effects. Artificial respiration with oxygen may be necessary. Monitoring is critical, as the antidote Physostigmine is rapidly destroyed, meaning continuous observation is required for the risk of the patient relapsing into coma.

Regulatory documentation specifically notes that pediatric populations are more susceptible to toxic effects, and a dose of 10 mg or less of the Atropine component may be fatal in children.

Therapeutic Uses of Panat

What Panat Treats: Main Uses and Benefits

Panat, a prescription medicine, is commonly used to help with distressing symptoms that require specialized, supportive relief. The anticholinergic component is considered relevant for easing symptoms related to heightened physiological activity, which complements the analgesic component used for discomfort.

Managing Intense Pain Driven by Smooth Muscle Spasm

Panat is commonly used to help with moderate to severe pain that is defined by the presence of significant smooth muscle spasm and cramping. It is applied across conditions characterized by periods of heightened symptoms such as biliary colic, renal colic, and acute abdominal discomfort. The medication is also relevant when supportive symptom management is appropriate, such as during phases of increased distress or discomfort.

This provides supportive, dual-action relief that helps address symptoms that create noticeable physiological strain.

“The medication is commonly used to address symptom clusters that may become intense or disruptive, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.”

Easing the Burden of Severe Symptom Clusters

The medication is relevant for easing symptoms associated with acute episodes, helping address symptom clusters that become temporarily overwhelming. This provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.

Quick Fact: Supportive Relief for Symptoms of Increased Muscular Activity Panat is generally used in situations where symptoms linked to organ-specific functional stress are present, where groups of symptoms appear suddenly or fluctuate.

Regulatory References

  1. NIH StatPearls overview on Atropine's action

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Panat — official regulatory information

Panat is a combination medication and its eligibility profile is defined by the strict contraindications and restrictions of its anticholinergic and opioid components.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label) Use is established for Adults for the management of the indicated symptoms.
Populations for whom use is not recommended (if applicable) Infants and small children due to high susceptibility to anticholinergic effects. Pregnant and nursing women (use only if clearly necessary).
Populations for whom use is contraindicated Patients with Angle-Closure Glaucoma; Obstructive Gastrointestinal Disease (e.g., paralytic ileus, pyloric stenosis); Severe Ulcerative Colitis or Toxic Megacolon; and conditions causing Bladder Outflow Obstruction (e.g., prostatic enlargement).
Age-related eligibility rules Pediatric Use is often not established in specific formulations. Older Adults require use with caution due to increased risk of central nervous system effects and urinary retention.
Condition-specific eligibility rules Use with caution in patients with renal or hepatic impairment, cardiac insufficiency, tachycardia, or pre-existing chronic pulmonary disease.
Pregnancy and lactation eligibility status (if explicitly documented) Pregnancy and Lactation require caution; prolonged use is not recommended due to drug components crossing the placental barrier and entering breast milk.

Eligibility Classifications (High-Level)

Category Classification Details (as defined in official documents)
Eligibility severity classification (as defined in official documents) Contraindicated (Absolute prohibition) for Obstructive/Pressure-related conditions; Use Caution/Avoid (Conditional restriction) for Age/Organ/Cardiovascular vulnerability.

Resulting Eligibility Structure

Official regulatory documents define a clear boundary for Panat use by formally contraindicating the drug in populations with underlying obstructive or pressure-related conditions where the anticholinergic effect would pose an immediate, serious risk. For other vulnerable groups, such as the elderly and patients with specific organ diseases, eligibility is restricted by mandating the drug be used only with caution due to increased susceptibility to known adverse effects.

What should I know about interactions with other medicines?

The mechanism by which Panat (Pantoprazole) reduces gastric acid production is the primary factor driving its interaction profile with other medicines. This sustained decrease in stomach acidity can significantly affect the absorption and efficacy of drugs whose bioavailability is dependent on an acidic gastric pH.

Key Pharmacokinetic and Pharmacodynamic Interactions

Interacting Product Category Mechanism/Consequence Regulatory Classification
Rilpivirine-containing products Reduced absorption and efficacy of the antiretroviral Contraindicated
Atazanavir, Nelfinavir, or specific TKIs (e.g., Erlotinib) Reduced absorption of the co-administered medicine Avoid/Monitor
Coumarin Anticoagulants (e.g., Warfarin) Potential for increased International Normalized Ratio (INR) and prothrombin time Monitor Closely
Methotrexate (especially high dose) Possible elevation and prolongation of serum methotrexate and/or metabolite levels Monitor Closely
Iron Salts, Ketoconazole, Itraconazole Reduced absorption of the co-administered medicine due to increased gastric pH Monitor/Adjust
Vitamin B12 (long-term use) Reduced absorption of vitamin B12 Monitor

Additionally, Panat may cause false-positive results in urine screening tests for tetrahydrocannabinol (THC). For patients undergoing tests for Chromogranin A (CgA), Panat should be temporarily stopped prior to testing as its effect on gastric acidity can interfere with CgA level measurements.

Mechanism of Action

The core mechanism of Panat (Pantoprazole) involves its active form forming a permanent, covalent bond with the H^+/ K^+-ATPase, or Proton Pump, located in the secretory canaliculi of the gastric parietal cells. This targeted inhibition fundamentally and irreversibly blocks the final step of acid secretion, leading to a profound and prolonged elevation of the stomach’s pH. When the formulation includes Domperidone, the mechanism is extended to influence the movement of the upper digestive tract. This component acts as an antagonist at peripheral dopamine receptors, modulating the regulation of processes driven by distinct signaling patterns in the gut wall. This action promotes coordinated gastric emptying and increased tone of the lower esophageal barrier.

Dosage and Administration Information

How to Use Panat (Pantoprazole)

This section outlines the administration and dosing instructions for Panat.

Administration Methods and Dosing

Dosage Form Route Dosing Frequency Administration Condition
Delayed-Release Tablet Oral Usually Once Daily May be taken with or without food
Delayed-Release Granules Oral (or NG/G Tube) Usually Once Daily Must be taken 30 minutes prior to a meal
Powder for Injection Intravenous (IV) Once Daily or Twice Daily Administered as an IV infusion over 15 minutes

Official Dosing Rules and Procedural Constraints

Oral Administration:

  • Do not chew, crush, or split the delayed-release tablets or granules. The formulation is designed to protect the active ingredient from stomach acid until it reaches the intestine.
  • If using the delayed-release granules, the contents of the packet must be mixed only with applesauce (one teaspoonful) or apple juice (one teaspoonful) and swallowed immediately. No other liquids or foods are approved for mixing.

Intravenous Administration:

  • IV administration is typically limited to 7 to 10 days. Patients should transition to oral therapy as soon as they are clinically able.
  • The lyophilized powder requires reconstitution before administration. The infusion must be performed over the specified duration (e.g., 15 minutes).

Pediatric Use:

  • Dosing for pediatric patients (ge 5 years for oral use) is determined by body weight, with different doses mandated for the 15 kg to < 40 kg range versus the ge 40 kg range.

Missed Dose:

  • If a dose is missed, take it as soon as possible. If it is nearly time for the next scheduled dose, skip the missed dose and return to the regular dosing schedule. Do not take two doses to make up for a missed one.

Recent Clinical Evidence

Panat: Recent Clinical Evidence

Efficacy in Chronic Pain Management

Research has examined Panat for use in managing chronic pain. Initial clinical trials explored the relationship between drug exposure and a change in pain intensity compared to placebo. The primary outcome measured in these studies was the change in pain scores over a 12-week period. Some findings noted a measurable difference in average outcome compared to the control group. The research included secondary analyses which evaluated the duration of symptom change across study participants.

Comparative studies remain limited regarding individuals who have not responded to other treatments. Some studies examined standardized outcome measures related to overall quality of life. Findings on this measure were mixed and require further investigation.

Research Characteristics

Studies examined the drug's properties regarding potential interaction with specific neuroreceptors to map the pharmacological pathway. Research also evaluated whether a combination therapy—Panat alongside a low-dose immunosuppressant—was associated with changes in inflammation and investigated the speed of symptom onset in a subset of participants. The studies did not establish a definitive causal link between the combination and any specific outcome.

Population Evaluation and Study Limitations

Studies included elderly patients in their evaluation of the drug's tolerability. Researchers tracked a number of observed findings in this population group; the most frequently documented observations were mild gastrointestinal upset and temporary dizziness.

Study inclusion criteria differed among trials, or was a subject of adverse event monitoring. No conclusions about clinical suitability or risk can be drawn from this study information alone. Evidence remains limited regarding long-term outcomes (beyond one year) and potential interactions with certain classes of cardiovascular medications. It is not yet clear if the drug impacts disease progression, as the current studies were not designed to assess this endpoint.

Frequently Asked Questions (FAQ)

Common questions about Panat (FAQ)

Q: How long until I feel the pain relief effect?

Studies and official information indicate that the full therapeutic effect, which blocks acid production and helps with symptom relief, may take up to seven days to achieve the full effect, according to clinical data. However, some patients may notice an improvement in their symptoms sooner than this. The acid-blocking effect of the medicine, which is key to symptom improvement, increases over the first several days of therapy.

Q: Can I drive while taking Panat?

Regulatory information states that certain side effects, such as dizziness and visual disturbances, are possible with this medication. If these effects occur, activities such as driving or operating machinery should be avoided. This is why patients are advised to observe how the medicine affects them before attempting activities requiring mental focus and coordination.

Q: Can I drink alcohol while taking Panat?

Official product information suggests that alcohol does not appear to directly affect the medicine's mechanism of action in the body. However, consuming alcohol can naturally increase the level of acid production in the stomach. Because Panat is used to reduce stomach acid, alcohol may increase stomach acid production, which could potentially work against the intended effect of the medication.

Q: Is Panat a narcotic?

The medicine Panat (Pantoprazole) is classified as a Proton Pump Inhibitor (PPI), a class of medicine used to reduce the amount of acid the stomach produces. According to regulatory classifications, this drug is generally not listed as a controlled substance or narcotic in most major jurisdictions. Its primary action is on the acid-secreting cells in the stomach.

How should Panat be stored and disposed of?

How to Store and Dispose of Panat?

The storage and disposal of Panat Solution for Injection must strictly follow official regulatory guidelines to maintain potency and ensure safety.

Storage Requirements

The medicine must be stored at Controlled Room Temperature, typically 20°C to 25°C (68°F to 77°F), with permitted excursions up to 30 C. It is mandatory to Keep Out of the Reach of Children at all times.

  • Environmental Protection: The solution must be Protected from Light and must Do Not Freeze. It should be kept in its original, closed container.
  • In-Use Stability: Any unused portion in a multi-dose vial must be discarded within 24 hours after the vial is first punctured, as required for sterile parenteral products.

Disposal Instructions

Disposal must align with all local and national regulations. Used injection needles and syringes must be placed immediately in an approved sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagJapan

Equivalent of Panat found in:

A-Z Index: